PH12017500239A1 - Abiraterone acetate formulation and methods of use - Google Patents
Abiraterone acetate formulation and methods of useInfo
- Publication number
- PH12017500239A1 PH12017500239A1 PH12017500239A PH12017500239A PH12017500239A1 PH 12017500239 A1 PH12017500239 A1 PH 12017500239A1 PH 12017500239 A PH12017500239 A PH 12017500239A PH 12017500239 A PH12017500239 A PH 12017500239A PH 12017500239 A1 PH12017500239 A1 PH 12017500239A1
- Authority
- PH
- Philippines
- Prior art keywords
- methods
- abiraterone acetate
- acetate formulation
- formulation
- compositions
- Prior art date
Links
- 229960004103 abiraterone acetate Drugs 0.000 title abstract 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462052294P | 2014-09-18 | 2014-09-18 | |
| US14/707,922 US20150246060A1 (en) | 2013-03-15 | 2015-05-08 | Abiraterone Acetate Formulation and Methods of Use |
| PCT/US2015/050889 WO2016044701A1 (en) | 2014-09-18 | 2015-09-18 | Abiraterone acetate formulation and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12017500239A1 true PH12017500239A1 (en) | 2017-07-03 |
Family
ID=55533897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12017500239A PH12017500239A1 (en) | 2014-09-18 | 2017-02-09 | Abiraterone acetate formulation and methods of use |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3193857A4 (enExample) |
| JP (1) | JP2017528457A (enExample) |
| KR (2) | KR102491439B1 (enExample) |
| CN (1) | CN106687112A (enExample) |
| AP (1) | AP2017009804A0 (enExample) |
| AU (1) | AU2015317466A1 (enExample) |
| BR (1) | BR112017003219A2 (enExample) |
| CA (1) | CA2958316A1 (enExample) |
| CO (1) | CO2017002472A2 (enExample) |
| EA (1) | EA201790650A1 (enExample) |
| IL (1) | IL250270B (enExample) |
| MD (1) | MD20170048A2 (enExample) |
| MX (1) | MX2017003525A (enExample) |
| PH (1) | PH12017500239A1 (enExample) |
| SG (1) | SG11201701139YA (enExample) |
| TN (2) | TN2018000318A1 (enExample) |
| WO (1) | WO2016044701A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| CA3061267A1 (en) * | 2017-04-07 | 2018-10-11 | Maa Laboratories, Inc. | Methods of improving the solubility and bioavailability of therapeutic agents |
| JP2022523704A (ja) * | 2019-01-25 | 2022-04-26 | シェンチェン・ファーマシン・カンパニー・リミテッド | 医薬組成物 |
| CN114026106B (zh) | 2019-03-06 | 2025-01-21 | 普洛拉治疗公司 | 阿比特龙前药 |
| CN110742870B (zh) * | 2019-12-04 | 2021-04-20 | 武汉大学 | 醋酸阿比特龙制剂及其制备方法 |
| CN111110646A (zh) * | 2020-02-19 | 2020-05-08 | 纳兰迦(上海)生物医药科技有限公司 | 一种低规格醋酸阿比特龙口服制剂的处方及制备方法 |
| CN113384542B (zh) * | 2020-03-14 | 2024-03-29 | 鲁南制药集团股份有限公司 | 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法 |
| US20230158047A1 (en) * | 2020-04-16 | 2023-05-25 | Tavanta Therapeutics Hungary Incorporated | Methods and compositions for treating prostate cancer |
| JP2023524794A (ja) * | 2020-05-08 | 2023-06-13 | ヤンセン ファーマシューティカ エヌ．ベー． | アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置 |
| EP3944860A1 (en) | 2020-07-30 | 2022-02-02 | Galenicum Health S.L.U. | Abiraterone for use in a method of treating cancer |
| CN117120034A (zh) | 2021-02-15 | 2023-11-24 | 普洛佩拉治疗公司 | 阿比特龙前药 |
| KR20240145412A (ko) | 2023-03-27 | 2024-10-07 | 한미약품 주식회사 | 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160148041A (ko) * | 2009-04-24 | 2016-12-23 | 아이슈티카 피티와이 리미티드 | 캅셀화된 나노입자의 상업적 규모의 생산 |
| GB201207886D0 (en) * | 2012-05-04 | 2012-06-20 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2014009436A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Nanosuspension of abiraterone acetate |
| WO2014009437A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Oxidation stability of abiraterone acetate |
| WO2014009434A1 (en) * | 2012-07-11 | 2014-01-16 | Sandoz Ag | Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate |
| CN102743393A (zh) | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | 一种含有醋酸阿比特龙的药物组合物及制备工艺 |
| TWI686212B (zh) * | 2013-03-15 | 2020-03-01 | 阿聯商太陽法瑪全球有限公司 | 醋酸阿比特龍配方 |
-
2015
- 2015-09-18 WO PCT/US2015/050889 patent/WO2016044701A1/en not_active Ceased
- 2015-09-18 MD MDA20170048A patent/MD20170048A2/ro not_active Application Discontinuation
- 2015-09-18 KR KR1020177008938A patent/KR102491439B1/ko active Active
- 2015-09-18 TN TNP/2018/000318A patent/TN2018000318A1/en unknown
- 2015-09-18 KR KR1020237001893A patent/KR102617537B1/ko active Active
- 2015-09-18 AP AP2017009804A patent/AP2017009804A0/en unknown
- 2015-09-18 CA CA2958316A patent/CA2958316A1/en active Pending
- 2015-09-18 JP JP2017512783A patent/JP2017528457A/ja active Pending
- 2015-09-18 EA EA201790650A patent/EA201790650A1/ru unknown
- 2015-09-18 EP EP15842591.8A patent/EP3193857A4/en not_active Withdrawn
- 2015-09-18 TN TN2017000098A patent/TN2017000098A1/en unknown
- 2015-09-18 MX MX2017003525A patent/MX2017003525A/es unknown
- 2015-09-18 BR BR112017003219A patent/BR112017003219A2/pt not_active IP Right Cessation
- 2015-09-18 SG SG11201701139YA patent/SG11201701139YA/en unknown
- 2015-09-18 CN CN201580050453.8A patent/CN106687112A/zh active Pending
- 2015-09-18 AU AU2015317466A patent/AU2015317466A1/en not_active Abandoned
-
2017
- 2017-01-25 IL IL250270A patent/IL250270B/en active IP Right Grant
- 2017-02-09 PH PH12017500239A patent/PH12017500239A1/en unknown
- 2017-03-15 CO CONC2017/0002472A patent/CO2017002472A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201701139YA (en) | 2017-03-30 |
| CO2017002472A2 (es) | 2017-07-11 |
| KR20230014878A (ko) | 2023-01-30 |
| TN2018000318A1 (en) | 2020-01-16 |
| JP2017528457A (ja) | 2017-09-28 |
| MD20170048A2 (ro) | 2017-08-31 |
| TN2017000098A1 (en) | 2018-10-19 |
| AU2015317466A1 (en) | 2017-02-23 |
| AP2017009804A0 (en) | 2017-03-31 |
| IL250270B (en) | 2021-02-28 |
| EP3193857A1 (en) | 2017-07-26 |
| WO2016044701A1 (en) | 2016-03-24 |
| BR112017003219A2 (pt) | 2017-11-28 |
| KR102491439B1 (ko) | 2023-01-25 |
| EP3193857A4 (en) | 2018-04-11 |
| CN106687112A (zh) | 2017-05-17 |
| MX2017003525A (es) | 2017-06-21 |
| KR102617537B1 (ko) | 2023-12-22 |
| IL250270A0 (en) | 2017-03-30 |
| KR20170070025A (ko) | 2017-06-21 |
| CA2958316A1 (en) | 2016-03-24 |
| EA201790650A1 (ru) | 2017-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004557B (en) | Modulatory polynucleotides | |
| TN2018000318A1 (en) | Abiraterone acetate formulation and methods of use. | |
| NZ712350A (en) | Abiraterone acetate formulation | |
| LT3224254T (lt) | Pakeistieji indazolai, jų gavimo būdas, juos turinčios farmacinės kompozicijos ir jų panaudojimas vaistų gamybai | |
| EP4620519A3 (en) | Methods and compositions relating to chondrisomes from blood products | |
| MY187540A (en) | Compounds active towards bromodomains | |
| IL273300A (en) | High dose valbenazine formulation and related preparations, methods and kits | |
| EP3177271A4 (en) | Liquid formulation compositions, medicament delivery devices, and methods of preparation and use thereof | |
| IL253793A0 (en) | Abiraterone acetate complexes, a process for their preparation and pharmaceutical preparations containing them | |
| MX2020004205A (es) | Composiciones antibioticas de ceftolozano. | |
| IN2014MU00303A (enExample) | ||
| EP3093023A4 (en) | Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient | |
| EP3177286A4 (en) | Compositions and methods for physiological delivery using cannabidiol | |
| IN2014CH00840A (enExample) | ||
| EP3151826A4 (en) | Omega-3 compositions, dosage forms, and methods of use | |
| EP3175851A4 (en) | Use of butenylphthalide, usage method thereof and method for preparing same into pharmaceutical composition | |
| HK1262230A1 (en) | Compositions and methods for delivery of therapeutic agents | |
| HK1239552A1 (en) | Compositions and method for physiological delivery using cannabidiol | |
| HK1234671A1 (en) | Omega-3 compositions, dosage forms, and methods of use | |
| GB201414271D0 (en) | Composition for delivery of an active pharmaceutical substance and method of preparing same | |
| MY180947A (en) | Ceftolozane antibiotic compositions | |
| IN2014CH01890A (enExample) |